Beam Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$18.24(as of Sep 4, 1:34 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Beam Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$18.24
Ticker SymbolBEAM
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees509
CountyUSA
Market Cap$1,650.0M
EBIDTA-424.0M
10-Day Moving Average16.69
P/E Ratio-4.80
20-Day Moving Average17.06
Forward P/E Ratio0.00
50-Day Moving Average18.69
Earnings per Share-4.50
200-Day Moving Average21.93
Profit Margin-1,208.26%
RSI58.45
Shares Outstanding101.2M
ATR1.12
52-Week High35.25
Volume8,596,397
52-Week Low13.53
Most Recent Support Level16.02
Book Value1,046.8M
Most Recent Resistance Level17.64
P/B Ratio1.83
Upper Keltner19.58
P/S Ratio31.75
Lower Keltner14.53
Debt-to-Equity Ratio19.58
Next Earnings Date11/10/2025
Cash Surplus108.0M
Next Ex-Dividend DateUnknown

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc In Our Stock Scanner

As of Sep 04, 2025
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.